Кардиоцитопротекторы — новое направление клинической кардиологии
Treatment and secondary prevention of cardiovascular diseases, which are based on coronary heart disease and hypertension, remains one of the most urgent problems of modern cardiology. Despite the success of coronary artery disease treatment it is obvious that the possibility of existing today hemod...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
SINAPS LLC
2011-02-01
|
| Series: | Архивъ внутренней медицины |
| Subjects: | |
| Online Access: | https://www.medarhive.ru/jour/article/view/9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Treatment and secondary prevention of cardiovascular diseases, which are based on coronary heart disease and hypertension, remains one of the most urgent problems of modern cardiology. Despite the success of coronary artery disease treatment it is obvious that the possibility of existing today hemodynamically active antianginal funds improving have been exhausted. In this context, particulary interesting is the new trend in the treatment of ischemic diseases — myocardial cytoprotection. In particular, myocardial cytoprotektor Mildronate limits manifestations of oxidative stress during ischemia, has a number of important effects, objectively improves the condition of patients, which allows it to be recommended as a necessary supplement to standard therapy. |
|---|---|
| ISSN: | 2226-6704 2411-6564 |